AR and prostate carcinoma: Importantly, NXP800 inhibited AR/AR-V7 transactivation and reduced AR DNA binding and expression of AR-responsive genes, as well as decreased the growth of prostate cancer cell lines and patient-derived models with common ARSI-resistant mechanisms, including AR amplification and AR-V7 protein expression.